AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12925049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of ANP (0.25 microg/kg/min in 0.9% NaCl) after 3 weeks' pre‐treatment with perindopril, 4 mg daily
Number of subjects: 7
Study 10840536 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 0.1 mg/kg body weight
Number of subjects: 98
Study 10840536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 9088077 — intervention group
Group type: EXPERIMENTAL
Intervention: LeukoNet prestorage leukoreduction filtration system
Number of subjects: 21
Study 9088077 — intervention group
Group type: COMPARATOR
Intervention: Control (non-leukoreduced units)
Number of subjects: 21
Study 8448775 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gum
Number of subjects: 10
Study 8448775 — intervention group
Group type: COMPARATOR
Intervention: No gum
Number of subjects: 10
Study 8448775 — intervention group
Group type: COMPARATOR
Intervention: Sucrose gum
Number of subjects: 10
Study 8448775 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol gum
Number of subjects: 10
Study 3082591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyloestradiol
Number of subjects: 5
Study 3082591 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Number of subjects: 5
Study 3082591 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 subjects)
Number of subjects: 5
Study 29555789 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodynamic management targeting StO2 >80%
Number of subjects: 103
Study 29555789 — intervention group
Group type: COMPARATOR
Intervention: Control group (no targeting StO2)
Number of subjects: 103
Study 28394110 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 40
Study 28394110 — intervention group
Group type: EXPERIMENTAL
Intervention: No corticosteroid therapy
Number of subjects: 40
Study 28394110 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 40
Study 24489014 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ORM-12741
Number of subjects: 12
Study 24489014 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ORM-12741
Number of subjects: 12
Study 24489014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22828645 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT booster dose
Number of subjects: 0
Study 22828645 — intervention group
Group type: EXPERIMENTAL
Intervention: MenC-TT booster dose
Number of subjects: 0
Study 22828645 — intervention group
Group type: COMPARATOR
Intervention: MenC-CRM197 (control group)
Number of subjects: 0
Study 22828645 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT and MenC-TT
Number of subjects: 0
Study 20153487 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 10
Study 18991470 — intervention group
Group type: EXPERIMENTAL
Intervention: TT (timolol/travoprost)
Number of subjects: 316
Study 18991470 — intervention group
Group type: COMPARATOR
Intervention: TL (timolol/latanoprost)
Number of subjects: 316
Study 15489260 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-trained (ET) men
Number of subjects: 36
Study 15489260 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (Sed) men
Number of subjects: 36
Study 14673126 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDIT
Number of subjects: 990
Study 14673126 — intervention group
Group type: EXPERIMENTAL
Intervention: CDT
Number of subjects: 990
Study 14673126 — intervention group
Group type: EXPERIMENTAL
Intervention: GGT
Number of subjects: 990
Study 9888118 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily contingent condition (earn a 1-day take-home privilege for each opiate and cocaine-free test delivered)
Number of subjects: 21
Study 9888118 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly contingent condition (three negative test results required for the first take-home privilege)
Number of subjects: 21
Study 9888118 — intervention group
Group type: COMPARATOR
Intervention: No take-home control
Number of subjects: 21
Study 9888118 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily contingent condition
Number of subjects: 21
Study 9888118 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly contingent condition
Number of subjects: 21
Study 8665128 — intervention group
Group type: EXPERIMENTAL
Intervention: Zamifenacin 30 mg
Number of subjects: 0
Study 8665128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8665128 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized planimetry
Number of subjects: 0
Study 1642946 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective blankets
Number of subjects: 30
Study 1642946 — intervention group
Group type: COMPARATOR
Intervention: No reflective blankets (Control)
Number of subjects: 30
Study 6099050 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil at 200 mg/day combined with gestagen at 50 mg/day
Number of subjects: 56
Study 6099050 — intervention group
Group type: COMPARATOR
Intervention: High dose estrogen (hexestrol at 60 mg/day)
Number of subjects: 56
Study 6099050 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil at 200 mg/day combined with hexestrol at 30 mg/day
Number of subjects: 56
Study 6099050 — intervention group
Group type: COMPARATOR
Intervention: High dose estrogen (hexestrol at 60 mg/day) in patients already well controlled
Number of subjects: 56
Study 31147254 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthostatic Hypotension (OH)
Number of subjects: 2275
Study 28646804 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-reduction program (EBT)
Number of subjects: 33
Study 28646804 — intervention group
Group type: COMPARATOR
Intervention: Intuitive eating (IE)
Number of subjects: 33
Study 27339107 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate solution (CHO)
Number of subjects: 12
Study 27339107 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% carbohydrate solution (CHO)
Number of subjects: 12
Study 27339107 — intervention group
Group type: COMPARATOR
Intervention: 0% control (PLA)
Number of subjects: 12
Study 24680406 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP
Number of subjects: 107
Study 24680406 — intervention group
Group type: EXPERIMENTAL
Intervention: SBiPAP
Number of subjects: 107
Study 24680406 — intervention group
Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 107
Study 22929967 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle treatment + daily topical application of diclofenac sodium
Number of subjects: 0
Study 22929967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20207879 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (N = 28)
Number of subjects: 55
Study 20207879 — intervention group
Group type: COMPARATOR
Intervention: Yogurt fluid (YF) (N = 27)
Number of subjects: 55
Study 20207879 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 55
Study 20207879 — intervention group
Group type: COMPARATOR
Intervention: Yogurt fluid (YF)
Number of subjects: 55
Study 17510867 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) laser transconjunctival blepharoplasty with resurfacing
Number of subjects: 36
Study 17510867 — intervention group
Group type: COMPARATOR
Intervention: CO(2) laser transcutaneous blepharoplasty by the skin‐muscle approach without resurfacing
Number of subjects: 36
Study 15913543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 59
Study 15913543 — intervention group
Group type: COMPARATOR
Intervention: Exposure and Response Prevention (ERP)
Number of subjects: 59
Study 11814510 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 343
Study 11814510 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 343
Study 11814510 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 343
Study 11814510 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy for prolapse
Number of subjects: 343
Study 11814510 — intervention group
Group type: COMPARATOR
Intervention: Overall sexual satisfaction
Number of subjects: 343
Study 9585947 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 98
Study 9585947 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 98
Study 9585947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 7650101 — intervention group
Group type: EXPERIMENTAL
Intervention: Neglect rehabilitation training for 2 months
Number of subjects: 0
Study 7650101 — intervention group
Group type: COMPARATOR
Intervention: General cognitive stimulation for 2 months (Control)
Number of subjects: 0
Study 2777423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 0.25%
Number of subjects: 22
Study 2777423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 0.50%
Number of subjects: 22
Study 2777423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 1%
Number of subjects: 22
Study 2777423 — intervention group
Group type: COMPARATOR
Intervention: Tropicamide 1%
Number of subjects: 22
Study 2777423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 1103551 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 1103551 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin
Number of subjects: 0
Study 31925942 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Number of subjects: 3412
Study 31925942 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms for PFS and OS
Number of subjects: 3412
Study 31070463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with clonidine 2 μg/kg
Number of subjects: 80
Study 31070463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine and a subcutaneous injection of clonidine 2 μg/kg (SC clonidine)
Number of subjects: 80
Study 31070463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with 1:400,000 adrenaline
Number of subjects: 80
Study 31070463 — intervention group
Group type: COMPARATOR
Intervention: 0.2% ropivacaine (control)
Number of subjects: 80
Study 28403589 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide 300 mg plus Alpha‐lipoic acid 300 mg (Peanase®)
Number of subjects: 44
Study 28403589 — intervention group
Group type: COMPARATOR
Intervention: Serenoa Repens at 320 mg
Number of subjects: 44
Study 25456116 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.5 μg · kg(‐1) initial dose followed by 0.4 μg · kg(‐1) h(‐1))
Number of subjects: 40
Study 25456116 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (NS group)
Number of subjects: 40
Study 23832382 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal right ventricular (RV) entrainment
Number of subjects: 42
Study 23832382 — intervention group
Group type: COMPARATOR
Intervention: Apical right ventricular (RV) entrainment
Number of subjects: 42
Study 21743879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/d
Number of subjects: 46
Study 19186907 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit information customization
Number of subjects: 0
Study 19186907 — intervention group
Group type: EXPERIMENTAL
Intervention: Configural customization
Number of subjects: 0
Study 19186907 — intervention group
Group type: EXPERIMENTAL
Intervention: Either or both forms of customization
Number of subjects: 0
Study 16702079 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 1
Study 16702079 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 1
Study 10225157 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 90
Study 8934993 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination IAN block and PDL injections using 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 40
Study 8934993 — intervention group
Group type: COMPARATOR
Intervention: Combination IAN block and mock PDL injections (needle penetration only)
Number of subjects: 40
Study 1927301 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser evaporation
Number of subjects: 204
Study 1927301 — intervention group
Group type: COMPARATOR
Intervention: Cryocoagulation
Number of subjects: 204
Study 6957127 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 50
Study 6957127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30638863 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS410 4000 mg
Number of subjects: 150
Study 30638863 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS410 2000 mg
Number of subjects: 150
Study 30638863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 30073693 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose cyclosporine A
Number of subjects: 0
Study 30073693 — intervention group
Group type: COMPARATOR
Intervention: Standard dose cyclosporine A
Number of subjects: 0
Study 27806350 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Docosahexaenoic Acid (DHA)
Number of subjects: 35
Study 27806350 — intervention group
Group type: COMPARATOR
Intervention: Sunflower Oil (SO)
Number of subjects: 35
Study 25304255 — intervention group
Group type: COMPARATOR
Intervention: Educational material (usual care comparison)
Number of subjects: 262
Study 25304255 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback of practice rates of high-risk prescribing
Number of subjects: 262
Study 25304255 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-informed behaviour change component
Number of subjects: 262
Study 22152405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 50
Study 22152405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21198224 — intervention group
Group type: EXPERIMENTAL
Intervention: BASICS
Number of subjects: 207
Study 21198224 — intervention group
Group type: COMPARATOR
Intervention: Alcohol 101
Number of subjects: 207
Study 21198224 — intervention group
Group type: COMPARATOR
Intervention: e-CHUG
Number of subjects: 207
Study 21198224 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only
Number of subjects: 207
Study 17674638 — intervention group
Group type: EXPERIMENTAL
Intervention: Dr. Dean Ornish Program for Reversing Heart Disease
Number of subjects: 93
Study 17674638 — intervention group
Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation
Number of subjects: 93
Study 16140544 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual piroxicam‐FDDF 20 mg/day
Number of subjects: 30
Study 16140544 — intervention group
Group type: COMPARATOR
Intervention: oral azithromycin 500 mg/day
Number of subjects: 30
Study 16140544 — intervention group
Group type: EXPERIMENTAL
Intervention: piroxicam‐FDDF 20 mg/day plus azithromycin 500 mg/day
Number of subjects: 30
Study 16140544 — intervention group
Group type: EXPERIMENTAL
Intervention: piroxicam‐FDDF 20 mg/day
Number of subjects: 30
Study 16140544 — intervention group
Group type: COMPARATOR
Intervention: azithromycin 500 mg/day
Number of subjects: 30
Study 12047415 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐284756 100 mg
Number of subjects: 40
Study 12047415 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐284756 200 mg
Number of subjects: 40
Study 12047415 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐284756 400 mg
Number of subjects: 40
Study 12047415 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐284756 800 mg
Number of subjects: 40
Study 12047415 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐284756 1200 mg
Number of subjects: 40
Study 12047415 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐284756 (all doses)
Number of subjects: 40
Study 10209367 — intervention group
Group type: EXPERIMENTAL
Intervention: Air
Number of subjects: 3
Study 10209367 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas mix (nitrous oxide and oxygen)
Number of subjects: 3
Study 10209367 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline
Number of subjects: 3
Study 7603807 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glycerol (GLY)
Number of subjects: 122
Study 7603807 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexamethasone (DXM)
Number of subjects: 122
Study 7603807 — intervention group
Group type: COMPARATOR
Intervention: Neither treatment (Control)
Number of subjects: 122
Study 2168694 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic resection after serologic remission
Number of subjects: 28
Study 2168694 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant cytoreductive procedures
Number of subjects: 28
Study 2168694 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic classification system
Number of subjects: 28
Study 30562274 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric contact lenses (1‐Day ACUVUE MOIST for astigmatism)
Number of subjects: 60
Study 30562274 — intervention group
Group type: COMPARATOR
Intervention: Spherical contact lenses (1‐Day ACUVUE MOIST)
Number of subjects: 60
Study 28500020 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-guided app recommendation service ('The Toolbox')
Number of subjects: 387
Study 28500020 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 387
Study 27100702 — intervention group
Group type: EXPERIMENTAL
Intervention: Aided suppression (substitute words provided)
Number of subjects: 72
Study 27100702 — intervention group
Group type: COMPARATOR
Intervention: Unaided suppression (no substitute words provided)
Number of subjects: 72
Study 27100702 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphoric participants
Number of subjects: 72
Study 27100702 — intervention group
Group type: COMPARATOR
Intervention: Non-dysphoric participants
Number of subjects: 72
Study 23775755 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact exercise (supervised progressive exercise three times a week for 12 months)
Number of subjects: 80
Study 23775755 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonintervention)
Number of subjects: 80
Study 23775755 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact exercise
Number of subjects: 80
Study 23775755 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 21909816 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline-saline solution 1:200,000
Number of subjects: 61
Study 21909816 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 61
Study 20555371 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (CIT) 0.5 g.kg‐1 body mass
Number of subjects: 13
Study 17576847 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg flucloxacillin
Number of subjects: 10
Study 17576847 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg flucloxacillin
Number of subjects: 10
Study 17576847 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/day continuous or prolonged infusion
Number of subjects: 10
Study 17576847 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term infusions of 6 g/day
Number of subjects: 10
Study 16361169 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic small incision (average length of incision, 12.7 cm)
Number of subjects: 386
Study 16361169 — intervention group
Group type: COMPARATOR
Intervention: Standard thoracic incision (control group)
Number of subjects: 386
Study 11953813 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0
Study 11953813 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian trial design
Number of subjects: 0
Study 10204902 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of 2% mepivacaine
Number of subjects: 120
Study 10204902 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL of 2% mepivacaine
Number of subjects: 120
Study 10204902 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mL of 2% mepivacaine
Number of subjects: 120
Study 10204902 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mL of 2% mepivacaine
Number of subjects: 120
Study 10204902 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 2% mepivacaine
Number of subjects: 120
Study 10204902 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mL of 2% mepivacaine
Number of subjects: 120
Study 7618660 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 5 mg.kg‐1
Number of subjects: 9
Study 7618660 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1
Number of subjects: 9
Study 2211767 — intervention group
Group type: EXPERIMENTAL
Intervention: Keller's arthroplasty
Number of subjects: 81
Study 2211767 — intervention group
Group type: COMPARATOR
Intervention: Arthrodesis
Number of subjects: 81
Study 659115 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallikrein (Padutin 100)
Number of subjects: 90
Study 659115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 30585111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 60
Study 30585111 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 60
Study 29016479 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam Rolling (20 minutes of FR exercises on quadriceps, hamstrings, adductors, gluteals, and gastrocnemius)
Number of subjects: 18
Study 29016479 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery (20 minutes sit on a bench)
Number of subjects: 18
Study 28615651 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐MCT (Metacognitive Training for Depression)
Number of subjects: 84
Study 28615651 — intervention group
Group type: COMPARATOR
Intervention: Active control intervention
Number of subjects: 84
Study 26360975 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit balance training
Number of subjects: 60
Study 26360975 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise
Number of subjects: 60
Study 23905568 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation clinic (RC)
Number of subjects: 19
Study 23905568 — intervention group
Group type: COMPARATOR
Intervention: Control group (discharged in 2008)
Number of subjects: 19
Study 21448197 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin (10 μg kg(‐1) subcutaneously)
Number of subjects: 20
Study 21448197 — intervention group
Group type: COMPARATOR
Intervention: Control (no darbepoetin)
Number of subjects: 20